Equities

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.94
  • Today's Change0.04 / 0.82%
  • Shares traded344.87k
  • 1 Year change+40.74%
  • Beta0.7443
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

  • Revenue in USD (TTM)190.86m
  • Net income in USD-16.39m
  • Incorporated2002
  • Employees203.00
  • Location
    Vanda Pharmaceuticals IncSUITE 300E, 2200 PENNSYLVANIA AVE NWWASHINGTON 20037United StatesUSA
  • Phone+1 (202) 734-3400
  • Fax+1 (202) 296-1450
  • Websitehttps://www.vandapharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
VNDA:NMQ since
announced
Transaction
value
Actelion Pharmaceuticals Ltd-PONVORYDeal completed07 Dec 202307 Dec 2023Deal completed22.28%100.00m
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Atea Pharmaceuticals Inc0.00-174.01m274.50m75.00--0.5987-----2.07-2.070.005.430.00----0.00-31.67-5.90-32.99-6.98-------38.91----0.00-------17.30------
Lexicon Pharmaceuticals Inc5.23m-216.39m278.96m285.00--1.56--53.35-0.7513-0.75130.0180.49380.01750.69553.2518,347.37-72.42-24.41-81.77-29.0193.5498.49-4,138.33-84.927.43-12.320.3588--766.19-54.71-73.74--37.68--
Tevogen Bio Holdings Inc0.0057.92m279.86m17.004.36------0.37580.37580.00-0.04520.00----0.001,217.57-----------------702.58--------99.69------
Rezolute Inc0.00-69.31m281.60m59.00--2.37-----1.27-1.270.002.050.00----0.00-58.64-50.36-62.66-53.25------------0.00-------32.19------
C4 Therapeutics Inc33.67m-105.50m283.06m145.00--1.17--8.41-1.70-1.700.52173.440.095--6.21232,193.10-29.76-25.91-33.20-29.45-----313.35-292.35----0.00---33.251.40-3.37---8.68--
Aldeyra Therapeutics Inc0.00-44.80m286.43m10.00--3.37-----0.7538-0.75380.001.430.00----0.00-33.86-36.79-39.67-40.77------------0.1522------39.47------
Vanda Pharmaceuticals Inc.190.86m-16.39m288.04m203.00--0.5322--1.51-0.2824-0.28243.299.280.29679.305.30940,187.20-2.556.61-2.957.6293.6290.55-8.5915.184.84--0.000.00-24.27-0.0496-60.02-36.96-56.77--
Absci Corp4.21m-97.67m289.57m155.00--1.45--68.83-0.9357-0.93570.04021.760.0178--3.6627,141.94-41.42---46.85-------2,321.56-----157.350.0269---0.5046---5.40------
Voyager Therapeutics Inc163.78m25.88m296.12m162.009.240.89669.571.810.58760.58762.946.060.4545--14.291,011,012.007.180.63788.420.8203----15.801.30----0.000.00511.16101.01385.14---5.43--
SAGE Therapeutics Inc106.40m-337.59m296.69m487.00--0.5376--2.79-5.58-5.581.769.020.1354--5.24218,478.40-42.95-21.88-48.97-23.3091.7599.63-317.29-131.50----0.00--1,024.84-0.8606-1.63---28.01--
iTeos Therapeutics Inc35.00m-121.25m296.92m157.00--0.4701--8.48-3.15-3.150.906417.290.05--1.43222,929.90-17.315.84-18.167.02-----346.4422.09----0.000.00-95.29---216.54--68.45--
Nautilus Biotechnology Inc0.00-70.21m298.84m161.00--1.34-----0.561-0.5610.001.780.00----0.00-24.29---25.05--------------0.00-------9.93------
Compass Pathways PLC (ADR)0.00-144.32m304.47m186.00--1.58-----2.19-2.190.002.820.00----0.00-52.83-40.85-57.18-44.48------------0.1337-------29.46---12.68--
Aclaris Therapeutics Inc27.08m-37.00m308.58m91.00--2.37--11.40-0.5198-0.51980.38061.820.1352--78.61297,582.40-18.47-47.29-20.87-53.8753.5344.00-136.65-549.18----0.00--5.0338.41-1.81---0.703--
Data as of Nov 21 2024. Currency figures normalised to Vanda Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

43.53%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 20245.73m9.83%
Renaissance Technologies LLCas of 30 Sep 20244.01m6.88%
The Vanguard Group, Inc.as of 30 Sep 20243.57m6.13%
Tang Capital Management LLCas of 30 Sep 20242.35m4.04%
Dimensional Fund Advisors LPas of 30 Sep 20242.13m3.66%
Acadian Asset Management LLCas of 30 Sep 20241.90m3.26%
Nantahala Capital Management LLCas of 30 Sep 20241.59m2.73%
Jacobs Levy Equity Management, Inc.as of 30 Sep 20241.43m2.45%
Geode Capital Management LLCas of 30 Sep 20241.43m2.45%
BlackRock Advisors LLCas of 30 Sep 20241.22m2.10%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.